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SHORT TAKE
Non cell autonomous upregulation of CDKN2 transcription
linked to progression of chronic hepatitis C disease
Mark W. Robinson,1* Dagmara McGuinness,2* Rachael
Swann,1,3 Stephen Barclay,4 Peter R. Mills,3 Arvind H. Patel,1
John McLauchlan1† and Paul G. Shiels2†
1MRC – University of Glasgow Centre for Virus Research, Glasgow, UK
2Section of Epigenetics, Institute of Cancer Sciences, MVLS, University of
Glasgow, Glasgow, UK
3Gartnavel General Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK
4Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde, Glasgow, UK
Summary
Chronic hepatitis C virus infection (C-HC) is associated with higher
mortality arising from hepatic and extrahepatic disease. This may
be due to accelerated biological aging; however, studies in C-HC
have thus far been based solely on telomere length as a
biomarker of aging (BoA). In this study, we have evaluated
CDKN2 locus transcripts as alternative BoAs in C-HC. Our results
suggest that C-HC induces non-cell-autonomous senescence and
accelerates biological aging. The CDKN2 locus may provide a link
between C-HC and increased susceptibility to age-associated
diseases and provides novel biomarkers for assessing its impact
on aging processes in man.
Key words: biological aging; CDKN2 locus; chronic HCV
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Introduction
Acute hepatitis C virus (HCV) infection is largely asymptomatic, and
chronic infection is often identified years later, following the develop-
ment of liver disease (Seeff, 2009). Due to the cumulative nature of
fibrosis and cirrhosis, HCV-related morbidity and mortality increase with
age (Grebely & Dore, 2011). Chronic HCV infection (C-HC) is also
associated with increased risk of extrahepatic diseases in the absence of
other comorbidities or risk behaviours (Grebely & Dore, 2011; Lee et al.,
2012), suggesting that C-HC alters the capacity of an individual to resist
the development of disease. It has been postulated that individuals with
C-HC undergo premature biological aging, with increased cellular
senescence, coincident with chronic inflammation and oxidative stress
(Hoare et al., 2010a), although the nature of any mechanistic link
remains to be determined. This hypothesis parallels observations in
human immunodeficiency virus (HIV)-infected patients who have a
higher than expected risk of complications typically associated with
aging (Deeks, 2011). While an independent association between age-
related diseases and HIV-induced aging has not been defined, the
elevated risk is consistent with the observation that infection increases
biomarkers associated with senescence commonly found in elderly
populations (Deeks, 2011).
How biomarkers of aging (BoA) differ between HCV-infected and
uninfected patients remains to be conclusively determined. Non-cell-
autonomous senescence as a consequence of viral infection could explain
the greater risk of age-related diseases in patients with C-HC. In patients
with C-HC, shorter telomere lengths are found in circulating leucocytes
(Kitay-Cohen et al., 2008), T cells (Hoare et al., 2010b) and liver biopsies
(Sekoguchi et al., 2007). However, recent studies highlight methodolog-
ical issues surrounding measurement of telomere length (Shiels, 2010;
Aviv et al., 2011). The cyclin-dependent kinase inhibitor (CDKN)2A has
been validated as an alternative BoA, which may represent a more
reproducible measure of biological age (Shiels, 2010). Elevated CDKN2A
transcription occurs with increasing age in both peripheral blood
leucocytes (Liu et al., 2009) and solid organs, where it correlates with
organ function (Koppelstaetter et al., 2008). In this study, we investi-
gated the correlation between C-HC and BoAs including telomere length,
CDKN2A and the related transcripts CDKN2B and ARF. We hypothesize
that viral persistence induces non-cell-autonomous senescence, which
may accelerate development of age-related diseases.
Study participants were recruited into two groups: healthy controls
(n = 24) who were negative for HCV-specific antibodies and patients
with C-HC (n = 43) who were positive for both HCV-specific antibodies
and viral RNA (Table S1). No significant differences were observed in
gender, ethnicity, age or body mass index of healthy controls and
patients with C-HC. Alanine transaminase values were significantly
higher in the C-HC group compared with controls consistent with the
presence of liver disease.
Higher expression of CDKN2A (P = 0.0002), ARF (P = 0.0008) and
CDKN2B (P = 0.0002) was observed in peripheral blood mononuclear
cells (PBMCs) of patients with C-HC, compared with healthy controls
(Fig. 1A and B, and Table S1). Elevated expression of CDKN2A
transcripts coincided with increased p16 protein levels in PBMCs from
patients with C-HC (Fig.S1). By contrast, no statistical difference was
found in relative telomere length (P = 0.2176, Fig. 1C). To investigate
whether these biomarkers were altered due to disease state or viral
genotype, the C-HC group was divided according to the presence or
absence of liver cirrhosis (measured by transient elastography) and viral
genotype (either genotype 1 or genotype 3). In patients with liver
cirrhosis (n = 14), expression of CDKN2A and ARF was significantly
higher compared with those without liver cirrhosis (n = 27) (Fig. 2A).
CDKN2B expression and p16 protein levels showed the same trend
although they failed to reach statistical significance (Fig. 2A and
Fig. S1C). No significant differences were noted in relative telomere
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length between C-HC patients with or without liver cirrhosis (Fig. 2B).
Separating the patients with C-HC according to viral genotype (geno-
type 1 (n = 23) and genotype 3 (n = 18)) showed no difference in
telomere length or expression of CDKN2 locus transcripts (Supplemen-
tary Fig. 2).
Elevated transcription of CDKN2A, ARF and CDKN2B in PBMC is
consistent with C-HC-associated non-cell-autonomous senescence,
resulting in increased biological aging in infected patients. This finding
supports reports linking accelerated aging and HCV (Kitay-Cohen et al.,
2008; Hoare et al., 2010b) and implies that C-HC indirectly drives the
development of senescence in PBMCs. While a trend towards decreasing
telomere length in C-HC patients with cirrhosis was seen, unlike previous
findings, HCV infection was not associated with a significant decrease in
telomere length (Kitay-Cohen et al., 2008; Hoare et al., 2010b). This
difference is likely due to the use of different techniques and highlights
the issues surrounding the use of any single measure as a definitive BoA
(Shiels, 2010; Aviv et al., 2011).
Our findings indicate that increased CDKN2 locus transcription in
PBMCs is a surrogate marker for the degree of liver damage, with the
highest expression levels of these BoAs noted in C-HC patients with
cirrhosis. Whether this is due solely to the progression of HCV infection or
alternatively whether liver cirrhosis independently induces senescence is
unknown. Elevated liver fibrosis and cirrhosis have been reported in mice
where the p53-dependent senescence programme had been ablated
(Lujambio et al., 2013). In this study, the inductionof p53-dependent non-
cell-autonomous senescence acts tomaintain organ integrity and suppress
liver damage; our findings are consistent with this model and provide
biomarkers for exploring this in in vivo human studies.
The observation of altered CDKN2 locus transcription, in association
with HCV infection, is consistent with non-cell-autonomous senescence.
Our study provides biomarkers for addressing the role of senescence in
C-HC infection and may aid patient management as prognostic tools for
the progression of liver disease and the development of extrahepatic
complications.
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Fig. 1 Expression of CDKN2 locus
transcripts and relative telomere length in
patients with C-HC and healthy controls.
Heat map (A) and expression profile (B) of
CDKN2 locus transcripts from patients with
C-HC (H; n = 41) and healthy controls (C;
n = 22). (C) Relative telomere length in
whole blood from patients with C-HC
(n = 42) compared with healthy controls
(n = 24). Data are presented as mean with
95% confidence intervals; ***denotes
P < 0.001.
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Fig. 2 Expression of CDKN2 locus
transcripts and relative telomere length in
C-HC patients with/without liver cirrhosis
and healthy controls. (A) Expression of
CDKN2 locus transcripts from C-HC
patients with (n = 14) or without (n = 27)
liver cirrhosis compared with healthy
controls. (B) Relative telomere length in
whole blood from C-HC patients with
(n = 15) or without (n = 27) liver cirrhosis
compared with healthy controls. Data are
presented as mean with 95% confidence
intervals; *P < 0.05, ***P < 0.001.
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